These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 26428356)

  • 1. Chemical characteristics for optimizing CYP2E1 inhibition.
    van de Wier B; Balk JM; Bast A; Koek GH; Haenen GR
    Chem Biol Interact; 2015 Dec; 242():139-44. PubMed ID: 26428356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An improved in vitro method for screening toxin and medicine targeting CYP2E1.
    Wang M; Zhou Z; Wang J; Zhang X
    Environ Toxicol Pharmacol; 2016 Oct; 47():86-91. PubMed ID: 27653210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pioglitazone, quercetin and hydroxy citric acid effect on cytochrome P450 2E1 (CYP2E1) enzyme levels in experimentally induced non alcoholic steatohepatitis (NASH).
    Surapaneni KM; Priya VV; Mallika J
    Eur Rev Med Pharmacol Sci; 2014; 18(18):2736-41. PubMed ID: 25317811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The discovery of the microsomal ethanol oxidizing system and its physiologic and pathologic role.
    Lieber CS
    Drug Metab Rev; 2004 Oct; 36(3-4):511-29. PubMed ID: 15554233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of reactive oxygen species (ROS) and cytochrome P-450 2E1 in the generation of carcinogenic etheno-DNA adducts.
    Linhart K; Bartsch H; Seitz HK
    Redox Biol; 2014; 3():56-62. PubMed ID: 25462066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis.
    Weltman MD; Farrell GC; Hall P; Ingelman-Sundberg M; Liddle C
    Hepatology; 1998 Jan; 27(1):128-33. PubMed ID: 9425928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug targeting CYP2E1 for the treatment of early-stage alcoholic steatohepatitis.
    Diesinger T; Buko V; Lautwein A; Dvorsky R; Belonovskaya E; Lukivskaya O; Naruta E; Kirko S; Andreev V; Buckert D; Bergler S; Renz C; Schneider E; Kuchenbauer F; Kumar M; Günes C; Büchele B; Simmet T; Müller-Enoch D; Wirth T; Haehner T
    PLoS One; 2020; 15(7):e0235990. PubMed ID: 32701948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased expression of cytochrome P450 2E1 in nonalcoholic fatty liver disease: mechanisms and pathophysiological role.
    Aubert J; Begriche K; Knockaert L; Robin MA; Fromenty B
    Clin Res Hepatol Gastroenterol; 2011 Oct; 35(10):630-7. PubMed ID: 21664213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Translational Implications of the Alcohol-Metabolizing Enzymes, Including Cytochrome P450-2E1, in Alcoholic and Nonalcoholic Liver Disease.
    Song BJ; Akbar M; Jo I; Hardwick JP; Abdelmegeed MA
    Adv Pharmacol; 2015; 74():303-72. PubMed ID: 26233911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of CYP2E1 leads to decreased advanced glycated end product formation in high glucose treated ADH and CYP2E1 over-expressing VL-17A cells.
    Swaminathan K; Kumar SM; Clemens DL; Dey A
    Biochim Biophys Acta; 2013 Oct; 1830(10):4407-16. PubMed ID: 23707663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression and activity of the cytochrome P450 2E1 in patients with nonalcoholic steatosis and steatohepatitis.
    Chtioui H; Semela D; Ledermann M; Zimmermann A; Dufour JF
    Liver Int; 2007 Aug; 27(6):764-71. PubMed ID: 17617119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis.
    Leclercq IA; Farrell GC; Field J; Bell DR; Gonzalez FJ; Robertson GR
    J Clin Invest; 2000 Apr; 105(8):1067-75. PubMed ID: 10772651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Study of cytochrome P450 2E1 and its allele variants in liver injury of nondiabetic, nonalcoholic steatohepatitis obese women.
    Varela NM; Quiñones LA; Orellana M; Poniachik J; Csendes A; Smok G; Rodrigo R; Cáceres DD; Videla LA
    Biol Res; 2008; 41(1):81-92. PubMed ID: 18769766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CYP2E1 and oxidant stress in alcoholic and non-alcoholic fatty liver disease.
    Leung TM; Nieto N
    J Hepatol; 2013 Feb; 58(2):395-8. PubMed ID: 22940046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relevance of CYP2E1 to non-alcoholic fatty liver disease.
    Daly AK
    Subcell Biochem; 2013; 67():165-75. PubMed ID: 23400921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The CYP2E1 knockout delivers another punch: first ASH, now NASH. Alcoholic steatohepatitis. Nonalcoholic steatohepatitis.
    Maher J
    Hepatology; 2001 Jan; 33(1):311-2. PubMed ID: 11124851
    [No Abstract]   [Full Text] [Related]  

  • 17. Cytochrome P450 2E1 contributes to ethanol-induced fatty liver in mice.
    Lu Y; Zhuge J; Wang X; Bai J; Cederbaum AI
    Hepatology; 2008 May; 47(5):1483-94. PubMed ID: 18393316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CYP2E1 induction leads to oxidative stress and cytotoxicity in glutathione-depleted cerebellar granule neurons.
    Valencia-Olvera AC; Morán J; Camacho-Carranza R; Prospéro-García O; Espinosa-Aguirre JJ
    Toxicol In Vitro; 2014 Oct; 28(7):1206-14. PubMed ID: 24929095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic variations of superoxide dismutase 2 and cytochrome P450 2E1 in non-alcoholic steatohepatitis.
    Huang YS; Chang CH; Lin TL; Perng CL
    Liver Int; 2014 Jul; 34(6):931-6. PubMed ID: 24649902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. End-product inhibition of skatole-metabolising enzymes CYP1A, CYP2A19 and CYP2E1 in porcine and piscine hepatic microsomes.
    Burkina V; Zlabek V; Rasmussen MK; Zamaratskaia G
    Toxicol Lett; 2019 Mar; 303():67-71. PubMed ID: 30599194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.